Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ON 108600
- Development stage
- Preclinical
- Lead developer
- Traws Pharma
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
ON 108600 is a novel, preclinical-stage small molecule multi-kinase inhibitor that simultaneously targets casein kinase 2 (CK2), TRAF2- and NCK-interacting kinase (TNIK), and dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK) family kinases. Developed by Traws Pharma (formerly Onconova Therapeutics) in collaboration with the Icahn School of Medicine at Mount Sinai, ON 108600 is designed to target breast cancer stem cell-like cells (BCSCs) and overcome chemotherapy resistance in triple-negative breast cancer (TNBC). By simultaneously inhibiting CK2, TNIK, and DYRK1, the compound induces G2/M cell cycle arrest and apoptosis in TNBC cells and cancer stem cells. Preclinical studies have demonstrated its efficacy in suppressing tumor growth and brain metastases in animal models of TNBC, both as a monotherapy and in combination with chemotherapy.
- Other names
- (E)-6-((2,6-dichlorobenzyl)sulfonyl)-2-(4-hydroxy-3-nitrobenzylidene)-2H-benzo[b][1,4]thiazin-3-ol
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CCND1 (Cyclin D1)CDKN1B (Transmembrane emp24 domain-containing protein 7)CK2 (Casein kinase II subunit alpha)CSNK2A2 (Casein kinase II subunit alpha prime)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)DYRK1B (Dual specificity tyrosine-phosphorylation-regulated kinase 1B)DYRK2 (Dual-specificity tyrosine-phosphorylation-regulated kinase 2)TNIK (TRAF2- and NCK-interacting kinase)
Beyond the preview
Go deeper on ON 108600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ON 108600.